Group 1 - Heptagon Pharma announced the latest progress in its core patent rights protection, with the National Intellectual Property Administration maintaining the validity of its "combination molecule" patent, which involves the use of transgenic animals to produce fully human heavy chain antibodies (HCAb) [1] - The "combination molecule" patent is central to Heptagon Pharma's Harbour Mice® platform, which has established collaborations with several well-known pharmaceutical companies globally, indicating significant commercial value [1] Group 2 - Yunnan Baiyao's JZ-14 capsule, a first-in-class small molecule immunomodulator developed by its subsidiary, has received clinical trial approval, showing significant immunomodulatory and anti-proliferative activity in ulcerative colitis and various tumor models [2] - Successful clinical translation of JZ-14 could fill a gap in the immunomodulation field and expand Yunnan Baiyao's presence in chemical drug innovation [2] Group 3 - Rongchang Bio's product, Taihetai (RC18), has received orphan drug designation from the European Commission for the treatment of myasthenia gravis, which provides various policy supports including scientific advice on development plans and a ten-year market exclusivity post-approval [3] Group 4 - Merck's Clesrovimab (MK-1654) injection application is proposed for priority review by the National Medical Products Administration, aimed at preventing lower respiratory tract infections caused by RSV in newborns and infants entering or born during the RSV season [4] - Clesrovimab's long-acting protective characteristics may alter the current RSV prevention landscape, necessitating attention to its competitive differentiation from vaccines and pricing strategies [4]

Core Points - The company is holding its annual general meeting to discuss various proposals, including financial reports and governance changes [1][3][19] - The meeting will take place on June 26, 2025, at 14:00 in Yantai, China, with both on-site and online voting options available [4][5][6] Meeting Procedures - Attendees must register and verify their identity to participate in the meeting [1][2] - Shareholders have the right to speak, ask questions, and vote on proposals, but must adhere to the meeting's agenda and time limits [2][3] - The meeting will be conducted in an orderly manner, with the chairman having the authority to manage discussions and responses to questions [2][3][4] Agenda Items - The meeting will review and vote on several key proposals, including: - The 2024 annual board report [8][10] - The 2024 annual supervisory report [10] - The 2024 financial settlement report, which has been audited and approved [11] - The 2024 annual report and its summary [12] - A proposal for profit distribution, indicating no distribution for 2024 [13] - The reappointment of accounting firms for 2025 [13] - Confirmation of director and supervisor remuneration for 2024 [14][18] - A proposal for general authorization to issue new shares [15][16] - Changes to the company's registered capital and governance structure, including the abolition of the supervisory board [17][21] - Amendments to the company's articles of association and meeting rules [19][20][22] Financial Performance - The company reported significant sales growth, particularly from its products, with a revenue of 1.699 billion yuan from one of its drugs [24] - The company is focused on maintaining high R&D investment while reducing net losses compared to previous years [24]

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2025-033 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 关于公司核心药品专利获得期限补偿的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，荣昌生物制药（烟台）有限公司（以下简称"公司"或"荣昌生物"）收到 国家知识产权局下发的《药品专利权期限补偿审批决定》，现将相关情况公告如下： 一、 涉及药品专利基本情况 专利号：ZL200710111162.2 专利名称：优化的 TACI-Fc 融合蛋白 专利申请日：2007 年 6 月 15 日 涉及药品：注射用泰它西普 二、 药品专利权期限补偿审批决定主要内容 按照中国专利法及其实施细则相关规定，决定给予该专利药品专利权期限补偿，补 偿天数 1827 天，原专利权期满终止日 2027 年 6 月 15 日，现专利权期满终止日 2032 年 6 月 15 日。药品专利权期限补偿期间，其保护范围限于国务院药品监 ...

Core Viewpoint - Rongchang Biopharma has received a patent term compensation decision from the National Intellectual Property Administration, extending the patent protection for its drug TACI-Fc fusion protein until June 15, 2032, which enhances its market exclusivity and competitive edge in the Chinese market [1] Summary by Relevant Sections - **Patent Information** - The patent number is ZL200710111162.2, with the application date of June 15, 2007, and the original expiration date of June 15, 2027 [1] - The compensation period granted is 1827 days, extending the patent protection [1] - **Impact on Company Strategy** - The extension aligns with the company's strategic development plan, providing an additional 5 years of market protection for its core product [1] - This extension is expected to significantly enhance the drug's exclusive sales window in the Chinese market, contributing to long-term performance growth and strengthening the company's core competitiveness [1]

Group 1 - The innovative drug sector is experiencing a downturn, with Rongchang Biologics falling over 7% [1] - Other companies such as Rundu Co., Ltd. (002923), Rejing Biologics, Warner Pharmaceuticals, and Wanbang Medicine (301520) also saw declines [1] - There is a disclosure of dark pool fund flows, indicating signals for early detection of stock accumulation by major investors [1]

暗盘资金正涌入这些股票，点击速看>>> 荣昌生物今日涨17.55%，成交额12.09亿元，换手率11.04%，盘后龙虎榜数据显示，沪股通专用席位买 入1.18亿元，三机构专用席位净买入1.44亿元，二机构专用席位净卖出1.93亿元。 ...

Group 1 - The core viewpoint of the news highlights the significant stock performance of Rongchang Biopharmaceuticals, with a notable increase in share price and trading volume, outperforming the Hang Seng Index [1] - As of June 12, the Hang Seng Index fell by 1.36%, while Rongchang Biopharmaceuticals' stock price rose by 20.1%, with a trading volume of 28.84 million shares and a turnover of 1.605 billion HKD [1] - Over the past month, Rongchang Biopharmaceuticals has seen a cumulative increase of 28.17%, and a year-to-date increase of 233.33%, surpassing the Hang Seng Index's growth by 21.47% [1] Group 2 - Financial data shows that as of March 31, 2025, Rongchang Biopharmaceuticals achieved total revenue of 526 million RMB, a year-on-year increase of 59.17%, and a net profit attributable to shareholders of -254 million RMB, with a growth of 27.16% [1] - The gross profit margin stands at 83.26%, and the debt-to-asset ratio is 66.62% [1] - Institutional ratings from Zhongtai International Securities Co., Ltd. give a "Buy" rating with a target price of 51.3 HKD [1] Group 3 - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 4.2 times, with a median of 6.01 times [1] - Rongchang Biopharmaceuticals has a P/E ratio of -18.33 times, ranking 107th in the industry [1] - Comparatively, other companies in the health sector have P/E ratios such as Dajiang International (0.56), Jingyou Pharmaceutical (0.68), Kingsray Biotechnology (1.6), Dongrui Pharmaceutical (3.08), and Charoen Pokphand International (3.16) [1] Group 4 - Rongchang Biopharmaceuticals was co-founded in 2008 by Wang Weidong and Dr. Fang Jianmin, with its headquarters located in Yantai, Shandong Province, China [2] - The company focuses on discovering, developing, producing, and commercializing innovative biopharmaceuticals targeting major diseases such as autoimmune disorders, tumors, and ophthalmology [2]

Group 1 - The Hong Kong stock market's innovative drug concept saw a strong performance in the afternoon, with Rongchang Biopharmaceutical and China National Pharmaceutical Group rising over 15% [1] - Other companies such as Junshi Biosciences, Zhaoyan New Drug (603127), BeiGene, and Kelun Pharmaceutical (002821) also experienced gains exceeding 5% [1] - Investors can buy Hong Kong stocks through A-share accounts without the need for the Hong Kong Stock Connect, allowing for T+0 trading [1]

荣昌生物制药（烟台）股份有限公司 董事会薪酬与考核委员会工作规则 第一章 总则 第一条 为进一步建立荣昌生物制药（烟台）股份有限公司（以下简称公司，连同 其附属公司，统称集团）健全的薪酬管理制度，完善公司治理结构，根据《中华人民共 和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券 法》）、《上市公司章程指引》、《上市公司治理准则》、公司股票上市地证券监管机 构的规定和上市规则等相关法律、法规以及《荣昌生物制药（烟台）股份有限公司章程》 （以下简称《公司章程》）的规定，特设立董事会薪酬与考核委员会，并制定本工作规 则。 第二条 薪酬与考核委员会是董事会下设的专门工作机构，主要负责研究董事及高级 管理人员的薪酬策略和政策、绩效评估及激励机制及其他与薪酬相关的事宜，并向董事会 提出建议。经董事会通过后，提呈股东会决议。 第三条 本工作规则所称的高级管理人员是指公司的总经理、首席财务官和董事会秘 书以及《公司章程》规定的其他高级管理人员。 第二章 组成 第四条 薪酬与考核委员会由三名或以上董事组成，直接由董事会委任，独立非执行 董事占大多数，主席由独立非执行董事担任。 第七条 薪酬与考核委 ...

荣昌生物制药（烟台）股份有限公司 独立董事工作制度 第一章 总则 第一条 为进一步完善荣昌生物制药（烟台）股份有限公司（以下简称公司） 的法人治理结构，改善董事会结构，强化对内部董事及经理层的约束和监督机制， 保护中小股东及债权人的利益，促进公司的规范运作，根据《中华人民共和国公 司法》（以下简称《公司法》）、《中华人民共和国证券法》《关于在上市公司中建 立独立董事制度的指导意见》《上市公司独立董事管理办法》（以下简称《管理办 法》），公司股票上市地证券监管机构的规定和上市规则等相关法律法规、规范性 文件和《荣昌生物制药（烟台）股份有限公司章程》（以下简称《公司章程》）的 有关规定，结合公司实际情况，特制订本制度。 第二条 独立董事是指不在公司担任除董事外的任何其他职务，并与公司及 公司主要股东、实际控制人不存在直接或者间接利害关系，或者可能妨碍其进行 独立客观判断的关系的董事。本制度所称"独立董事"为境内股票上市规则项下所 指含义，亦为《香港联合交易所股份有限公司证券上市规则》（以下简称《香港 上市规则》）项下的"独立非执行董事"。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当按 法律、 ...